Contractual Cash Flows. Disciplined Underwriting. Operator Edge.

Founder of IVEST Consumer Partners — a private equity firm with over $500 million in assets and portfolio retail sales surpassing $1.5 billion across 50 countries — and the exclusive strategic private equity partner of Licensing International. His career spans 18+ proprietary control investments across consumer, healthcare, and industrial businesses, roughly fifteen companies founded, and the $6 billion BCTel–Telus integration at Fujitsu.
An active angel investor in AI startups and longstanding healthcare investor, Sam leads origination, structuring, and underwriting at Signal — applying two decades of royalty and licensing discipline to contractual healthcare cash flows.

One of the world's foremost transplant surgeons — trained under Dr. Thomas E. Starzl at the University of Pittsburgh, Professor of Surgery at the UCLA School of Medicine, and Chairman of the Department of Surgery and Director of Transplantation Services at Cedars-Sinai Medical Center. His scientific record spans 378 peer-reviewed publications, seven books, and nine editorial boards.
Decades at the commercial interface of medicine — Pharmacia, United HealthCare, Tractus Medical — give Signal its clinical authority and its relationships across pharmaceutical companies, academic medicine, and hospital systems.
Accelerating deal flow, proven asset class resilience, and a competitive vacuum at the mid-market level.
Three established platforms define the healthcare royalties landscape. Each has moved upmarket or internalized, widening the mid-market gap.
Every investment is stress-tested across five dimensions before commitment.
Signal Royalty Partners employs a multi-channel origination strategy focused on identifying high-quality royalty opportunities in the $25–150 million range:
For qualified institutional investors and family offices.